In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company's shares closed last Tuesday at $87.03. According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -1.3% and a 32.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $98.20, a 14.1% upside from current levels.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-merck-company-mrk-3?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Merck Charts.